Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion - PubMed (original) (raw)

. 2007 Oct 1;121(7):1424-32.

doi: 10.1002/ijc.22862.

Affiliations

• PMID: 17551921
• DOI: 10.1002/ijc.22862

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion

Sanjeev Shukla et al. Int J Cancer. 2007.

Abstract

Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt/PKB are important signaling molecules and key survival factors involved in the control of cell proliferation, apoptosis and oncogenesis. We investigated the role of the PI3K-Akt signaling pathway in the invasion of prostate cancer cell lines and activation of this pathway in primary human prostate tumors. Treatment of human prostate cancer cells viz. LNCaP, PC-3 and DU145 with PI3K pharmacological inhibitor, LY294002, potentially suppressed the invasive properties in each of these cell lines. Restoration of the PTEN gene to highly invasive prostate cancer PC-3 cells or expression of a dominant negative version of the PI3K target, Akt also significantly inhibited invasion and downregulated protein expression of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase (MMP)-9, markers for cell invasion, indicating a central role of the PI3K-Akt pathway in this process. Immunoblot analysis of PI3K and total/activated levels of Akt showed increased protein levels of catalytic (p110alpha/beta) and regulatory (p85) subunits of PI3K and constitutive Akt activation in high-grade tumors compared to low-grade tumor and benign tissue. Immunohistochemical analyses further confirmed a progressive increase in p-Akt (p-Ser473) levels but not of total-Akt (Akt1/2) in cancer tissues compared to benign specimens. A successive increase in p-Akt expression was further noted in specimens serially obtained from individuals with time-course disease progression. Taken together, these results suggest that aberrant activation of PI3K-Akt pathway may contribute to increased cell invasiveness and facilitate prostate cancer progression.

PubMed Disclaimer

Similar articles

• Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
  Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austild-Taskén K, Abrahamsson PA. Dizeyi N, et al. Urol Oncol. 2011 Jul-Aug;29(4):436-45. doi: 10.1016/j.urolonc.2009.09.013. Epub 2009 Nov 19. Urol Oncol. 2011. PMID: 19926313
• PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
  Fang J, Ding M, Yang L, Liu LZ, Jiang BH. Fang J, et al. Cell Signal. 2007 Dec;19(12):2487-97. doi: 10.1016/j.cellsig.2007.07.025. Epub 2007 Aug 15. Cell Signal. 2007. PMID: 17826033 Free PMC article.
• [P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer].
  Wang YX, Shi YH, Gong LH, Li Y, Heng WJ, You JF, Zhong HH, Fang WG. Wang YX, et al. Zhonghua Bing Li Xue Za Zhi. 2007 Oct;36(10):681-6. Zhonghua Bing Li Xue Za Zhi. 2007. PMID: 18194602 Chinese.
• Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
  Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC. Das R, et al. IUBMB Life. 2005 Jun;57(6):441-7. doi: 10.1080/15216540500159424. IUBMB Life. 2005. PMID: 16012053 Review.
• Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
  Yan Y, Huang H. Yan Y, et al. Adv Exp Med Biol. 2019;1210:319-331. doi: 10.1007/978-3-030-32656-2_14. Adv Exp Med Biol. 2019. PMID: 31900915 Review.

Cited by

• CAVPENET Peptide Inhibits Prostate Cancer Cells Proliferation and Migration through PP1γ-Dependent Inhibition of AKT Signaling.
  Matos B, Gomes AAS, Bernardino R, Alves MG, Howl J, Jerónimo C, Fardilha M. Matos B, et al. Pharmaceutics. 2024 Sep 12;16(9):1199. doi: 10.3390/pharmaceutics16091199. Pharmaceutics. 2024. PMID: 39339236 Free PMC article.
• Dihydrotestosterone Enhances MICA-Mediated Immune Responses to Epstein-Barr Virus-Associated Gastric Carcinoma.
  Seo D, Byun H, Cho M, Lee SH, Youn S, Lee J, Jung I, Cho H, Kang H. Seo D, et al. Cancers (Basel). 2024 Sep 21;16(18):3219. doi: 10.3390/cancers16183219. Cancers (Basel). 2024. PMID: 39335190 Free PMC article.
• An insight into the anticancer potentials of lignan arctiin: A comprehensive review of molecular mechanisms.
  Chowdhury R, Bhuia MS, Wilairatana P, Afroz M, Hasan R, Ferdous J, Rakib AI, Sheikh S, Mubarak MS, Islam MT. Chowdhury R, et al. Heliyon. 2024 Jun 13;10(12):e32899. doi: 10.1016/j.heliyon.2024.e32899. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38988539 Free PMC article. Review.
• Regulation of Molecular Biomarkers Associated with the Progression of Prostate Cancer.
  Martin-Caraballo M. Martin-Caraballo M. Int J Mol Sci. 2024 Apr 10;25(8):4171. doi: 10.3390/ijms25084171. Int J Mol Sci. 2024. PMID: 38673756 Free PMC article. Review.
• Furanocoumarins as Enhancers of Antitumor Potential of Sorafenib and LY294002 toward Human Glioma Cells In Vitro.
  Sumorek-Wiadro J, Zając A, Skalicka-Woźniak K, Rzeski W, Jakubowicz-Gil J. Sumorek-Wiadro J, et al. Int J Mol Sci. 2024 Jan 7;25(2):759. doi: 10.3390/ijms25020759. Int J Mol Sci. 2024. PMID: 38255833 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal